

Second Quarter FY 2024 Results

Prestige Consumer HEALTHCARE

November 2nd, 2023

Safe Harbor Disclosure

This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, organic revenue growth, diluted EPS, free cash flow, and leverage; the Company's execution on its brand-building strategy; the expected market share and consumption trends for the Company's brands; the Company's expected growth, including with respect to online sales; and the Company's capital allocation strategy. Words such as "anticipate," "continue," "positioned," "will," "expect," "outlook," "focus," "may," "should," "could," "would," and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company's expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the impact of geopolitical instability, including on economic and business conditions; consumer trends; disruptions to manufacturing, distribution and supply chain and related price increases; labor shortages; competitive pressures; the impact of the Company's advertising and promotional and new product development initiatives; customer inventory management initiatives; the ability to pass along rising costs to customers without impacting sales; fluctuating foreign exchange rates; and other risks set forth in Part I, Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the year ended March 31, 2023. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise.

All adjusted GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedule or in our November 2, 2023 earnings release in the "About Non-GAAP Financial Measures" section.



- I. Performance Update
- **II.** Financial Overview
- III. FY 24 Outlook





I. Performance Update



Continued Strong Results in Q2 FY 24

Solid quarterly Revenue of \$286.3 million, similar to prior year's record level Q2 FY 24 Sales Consumers continue to seek the benefits of trusted consumer healthcare brands. Drivers Continue to benefit from leading & diversified portfolio Gross Margin as expected with sequential improvement **Superior Earnings** and FCF Solid financial profile and resulting Free Cash Flow⁽²⁾ generation Continued focus on disciplined capital allocation resulting in leverage of $3.0x^{(3)}$ **Disciplined Capital** Allocation Capital allocation priorities remain unchanged




Brand-Building through Robust Omnichannel Campaigns Goodules

0

New Collateral Across Social & Digital

Highly Visible National Media



- High-touch, omnichannel media driving awareness across channels
- Improved brand visibility connecting with new customers



National exposure on Amazon Prime Thursday Night Football Amazon brand store views more than doubled after 1st game

"Get to Good" Campaign Driving Consumption >3x the Category



Strong Online Growth via Strategic Conversion Campaigns



 Continued strong performance across all eCommerce partners







Engaging Content Driving Traffic & Conversion







PrestigeConsumer HEALTHCARE


*Retail sales as of 9.30.2023

II. Financial Overview



Second Quarter and 1H FY 24 Performance Highlights

HEALTHCARE



FY 24 Second Quarter and 1H Consolidated Financial Summary

| | 3 M | 6 Months Ended | | | | | | | |
|-------------------------------------|-------------------------|-------------------------|---------|----|-----------------------|------------|-----------------------|---------|----|
| | Q2 FY 24 | Q2 FY 23 | % Chg | 1 | H FY 24 | <u>1</u> H | FY 23 | % Chg | |
| Total Revenues | \$ 286.3 | \$ 289.3 | (1.0%) | \$ | 565.6 | \$ | 566.3 | (0.1%) | |
| Gross Margin % Margin | 160.0 55.9% | 161.0 55.7% | (0.6%) | | 314.7 55.6% | | 321.1 56.7% | (2.0%) | |
| A&M % Total Revenues | 40.1 <i>14.0%</i> | 43.8 15.1% | (8.5%) | | 76.3 13.5% | | 83.8 14.8% | (8.9%) | |
| G&A % Total Revenues | 26.0 <i>9</i> .1% | 26.4 9.1% | (1.7%) | | 53.7 9.5% | | 53.2 9.4% | 1.0% | |
| D&A | 5.7 | 6.4 | (10.9%) | | 11.2 | | 12.8 | (12.3%) | |
| Operating Income % Margin | \$ 88.3 30.8% | \$ 84.4 29.2% | 4.6% | \$ | 173.4 30.7% | \$ | 171.4 30.3% | 1.2% | i. |
| Diluted Earnings Per Share | \$ 1.07 | \$ 1.02 | 5.4% | \$ | 2.13 | \$ | 2.11 | 1.2% | |
| EBITDA % Margin | \$ 95.7 33.4% | \$ 91.8 31.7% | 4.2% | \$ | 189.6 33.5% | \$ | 186.4 32.9% | 1.7% | |

1H Comments

Organic Revenue⁽¹⁾ approximately flat vs. record PY, as expected

 Continued growth in eCommerce up mid-single-digits vs. PY

 Benefitting from effect of diverse portfolio

Gross Margin of 55.6% as expected

A&M of 13.5% of Revenues

G&A of 9.5% of Revenues, consistent with PY

Diluted EPS up slightly vs. PY

Dollar values in millions, except per share data; D&A excludes COGS D&A



Strong Free Cash Flow Enabling Reduced Leverage

| Free Cash Flow ⁽²⁾ | Comments |
|--|--|
| Q2 FY 24 Q2 FY 23 1H FY 24 (5.5%) (5.5%) 1 1 1 | Net Debt⁽²⁾ at September 30 of \$1.2 billion; leverage ratio⁽³⁾ of 3.0x at end of Q2 Aligned with long-term leverage⁽³⁾ target of less than 3.0x Capital allocation priorities remain unchanged |
| Prestige Consumer HEALTHCARE | SECOND QUARTER FY 24 RESULTS 11 |

III. FY 24 Outlook



Outlook: Staying the Strategic Course to Create Value

| Strategy delivering with growing and well-positioned business Agile brand-building positions portfolio for further growth Revenue of \$1,135 million to \$1,140 million Organic growth of 1% to 2% ex-FX Organic growth of 2% to 3% when excluding strategic exit of private label business |
|---|
| Anticipate diluted EPS at the higher end of the \$4.27 to \$4.32 outlook |
| Free Cash Flow⁽⁴⁾ of \$240 million or more Continue to execute disciplined capital allocation strategy Anticipate Net Debt / EBITDA below 3.0x by year-end FY 24 |
| |







Appendix

- (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measure in the attached Reconciliation Schedules and / or our earnings release dated November 2, 2023 in the "About Non-GAAP Financial Measures" section.
- (2) EBITDA & EBITDA Margin, Free Cash Flow, and Net Debt are Non GAAP financial measures and are reconciled to their most closely related GAAP financial measures in the attached Reconciliation Schedules and / or in our earnings release dated November 2, 2023 in the "About Non GAAP Financial Measures" section.
- (3) Leverage ratio reflects Net Debt / covenant defined EBITDA.
- (4) Free Cash Flow for FY 24 is a projected Non-GAAP financial measure, is reconciled to projected GAAP Net Cash Provided by Operating Activities in the attached Reconciliation Schedules and / or in our earnings release in the "About Non-GAAP Financial Measures" section and is calculated based on projected Net Cash Provided by Operating Activities less projected capital expenditures plus cash payments associated with discrete items.



Reconciliation Schedules

Organic Revenue Change

| | ٦ | Three Months Ended September 30, | | | | Six Months Ended September 30, | | | | |
|---|----|----------------------------------|----|---------|----|--------------------------------|----|---------|--|--|
| | | 2023 | | 2022 | | 2023 | | 2022 | | |
| (In Thousands) | | | | | | | | | | |
| GAAP Total Revenues | \$ | 286,316 | \$ | 289,273 | \$ | 565,625 | \$ | 566,332 | | |
| Revenue Change | | (1.0%) | | | | (0.1%) | | | | |
| Adjustments: | | | | | | | | | | |
| Impact of foreign currency exchange rates | | - | | (1,035) | | - | | (3,759) | | |
| Total adjustments | \$ | - | \$ | (1,035) | \$ | - | \$ | (3,759) | | |
| Non-GAAP Organic Revenues | \$ | 286,316 | \$ | 288,238 | \$ | 565,625 | \$ | 562,573 | | |
| Non-GAAP Organic Revenue Change | | (0.7%) | | | | 0.5% | | | | |

EBITDA Margin

| | T | Three Months Ended September 30, | | | | Six Months Ended September 30, | | | |
|-------------------------------|-----------|----------------------------------|------|--------|------|--------------------------------|----|---------|--|
| | 2023 2022 | | 2022 | | 2023 | 2022 | | | |
| <u>(In Thousands)</u> | | | | | | | | | |
| GAAP Net Income | \$ | 53,559 | \$ | 51,023 | \$ | 106,835 | \$ | 106,295 | |
| Interest expense, net | | 17,606 | | 16,979 | | 35,325 | | 32,271 | |
| Provision for income taxes | | 16,856 | | 15,570 | | 32,293 | | 31,195 | |
| Depreciation and amortization | | 7,643 | | 8,248 | | 15,186 | | 16,632 | |
| Non-GAAP EBITDA | | 95,664 | | 91,820 | | 189,639 | | 186,393 | |
| Non-GAAP EBITDA Margin | | 33.4% | | 31.7% | | 33.5% | | 32.9% | |



Reconciliation Schedules (Continued)

Free Cash Flow

| Three Months Ended September 30, | | | Six Months Ended September 30 | | | | |
|----------------------------------|----------|---|--|---|---|--|--|
| 2023 | | 2022 | | 2023 | | 2022 | |
| | | | | | | | |
| \$ | 53,559 | \$ | 51,023 | \$ | 106,835 | \$ | 106,295 |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | 19,862 | | 17,255 | | 38,050 | | 33,489 |
| | | | | | | | |
| | (10,961) | | (10,738) | | (34,338) | | (23,997) |
| | 8,901 | | 6,517 | | 3,712 | | 9,492 |
| | 62,460 | | 57,540 | | 110,547 | | 115,787 |
| | (2,934) | | (2,376) | | (4,411) | | (3,423) |
| | 59,526 | | 55,164 | | 106,136 | | 112,364 |
| | \$ | 2023 \$ 53,559 19,862 (10,961) 8,901 62,460 (2,934) | 2023 \$ 53,559 \$ 19,862 (10,961) 8,901 62,460 (2,934) | 2023 2022 \$ 53,559 \$ 51,023 19,862 17,255 (10,961) (10,738) 8,901 6,517 62,460 57,540 (2,934) (2,376) | 2023 2022 \$ 53,559 \$ 51,023 19,862 17,255 (10,961) (10,738) 8,901 6,517 62,460 57,540 (2,934) (2,376) | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ |

Projected Free Cash Flow

| (In millions) | |
|--|-----------|
| Projected FY'24 GAAP Net cash provided by operating activities | \$ 250 |
| Additions to property and equipment for cash | (10) |
| Projected Non-GAAP Free Cash Flow | 240 |

